(ELM-PC 5 Trial) Articles

SAN FRANCISCO, CA USA (UroToday.com) - Complete Title: GU Cancers Symposium 2014 - Session Highlights: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)

SAN FRANCISCO, CA USA (UroToday.com) - Complete Title: GU Cancers Symposium 2014 - Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial) - Abstract